Akeso’s Cadonilimab Gains Approval for First-Line Cervical Cancer Treatment

Akeso, Inc. ( (HK:9926) ) has issued an announcement.

Akeso, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for cadonilimab as a first-line treatment for cervical cancer. This approval marks a significant advancement in addressing the unmet needs for immune-based therapies in cervical cancer, offering a new treatment option for patients at all stages of the disease. The approval is based on successful results from the COMPASSION-16/AK104-303 study, which demonstrated improved progression-free and overall survival rates. This development positions Akeso as a leader in innovative cancer treatments, potentially impacting the company’s market presence and offering hope to stakeholders in the healthcare sector.

The most recent analyst rating on (HK:9926) stock is a Buy with a HK$58.97 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

More about Akeso, Inc.

Akeso, Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative immuno-therapies. The company is known for its first-in-class PD-1/CTLA-4 bi-specific antibody, cadonilimab, and is actively conducting clinical trials across various cancer indications.

Average Trading Volume: 14,789,869

Technical Sentiment Signal: Buy

Current Market Cap: HK$67.32B

Learn more about 9926 stock on TipRanks’ Stock Analysis page.